MREO Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.13%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $1,279,046.33

Mereo BioPharma Group Insider Trading History Chart

Mereo BioPharma Group Share Price & Price History

^$3.72

▲ +0.04 (1.09%)

As of 11/22/2024 01:00 AM ET

Days: 30 | 90 | 365

Trump won. Buy this coin now.

From Weiss Ratings | Ad

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.

Mereo BioPharma Group Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/12/2024	Charles Sermon	General Counsel	Sell	9,980	$4.47	$44,610.60	240,007
9/12/2024	Christine Ann Fox	CFO	Sell	9,128	$4.47	$40,802.16	108,443
9/12/2024	Denise Scots-Knight	CEO	Sell	28,611	$4.47	$127,891.17	868,967
9/12/2024	John A Lewicki	Insider	Sell	5,212	$4.47	$23,297.64	89,567
8/22/2024	Deepika Pakianathan	Director	Sell	105,244	$4.43	$466,230.92
6/25/2024	Charles Sermon	General Counsel	Sell	14,202	$3.69	$52,405.38	216,574
6/25/2024	Christine Ann Fox	CFO	Sell	12,990	$3.69	$47,933.10	87,010
6/25/2024	Denise Scots-Knight	CEO	Sell	40,712	$3.69	$150,227.28	801,791
6/25/2024	John A Lewicki	Insider	Sell	7,416	$3.69	$27,365.04	65,587
5/22/2024	Alexandra Hughes-Wilson	Insider	Sell	100,432	$2.97	$298,283.04	32,568

Trump Wins… But Elon Says Get Ready to Brace

From Genesis Gold Group | Ad

Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…

Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov

SEC Filings (Institutional Ownership Changes) for Mereo BioPharma Group (NASDAQ:MREO)

62.83% of Mereo BioPharma Group stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Mereo BioPharma Group Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/15/2024	Frazier Life Sciences Management L.P.	5,097,779	$20.95M	0.8%	+15.8%	3.635%
11/15/2024	State Street Corp	47,561	$0.20M	0.0%	N/A	0.034%
11/15/2024	Polar Asset Management Partners Inc.	198,300	$0.82M	0.0%	+36.0%	0.141%
11/15/2024	Janus Henderson Group PLC	12,345,866	$50.87M	0.0%	+56.7%	8.802%
11/15/2024	Clearline Capital LP	3,244,334	$13.33M	0.6%	-2.5%	2.313%
11/14/2024	Fred Alger Management LLC	102,582	$0.42M	0.0%	+108.1%	0.073%
11/14/2024	Verition Fund Management LLC	110,004	$0.45M	0.0%	-51.4%	0.078%
11/14/2024	Acuta Capital Partners LLC	1,260,700	$5.18M	4.2%	+86.2%	0.899%
11/12/2024	HealthInvest Partners AB	200,000	$0.82M	0.4%	N/A	0.143%
11/5/2024	GSA Capital Partners LLP	67,069	$0.28M	0.0%	N/A	0.048%
10/7/2024	GAMMA Investing LLC	10,693	$44K	0.0%	+58.1%	0.008%
8/16/2024	Perceptive Advisors LLC	1,253,250	$4.51M	0.1%	N/A	0.894%
8/16/2024	Forefront Analytics LLC	36,231	$0.13M	0.1%	-17.3%	0.026%
8/16/2024	Frazier Life Sciences Management L.P.	4,401,371	$15.85M	0.7%	N/A	3.138%
8/15/2024	Blue Owl Capital Holdings LP	897,809	$3.23M	0.9%	N/A	0.640%
8/15/2024	The Manufacturers Life Insurance Company	14,621	$53K	0.0%	-87.7%	0.010%
8/15/2024	Millennium Management LLC	3,201,705	$11.53M	0.0%	+46.9%	2.283%
8/15/2024	Deerfield Management Company L.P. Series C	6,710,429	$24.16M	0.4%	N/A	4.784%
8/14/2024	Fred Alger Management LLC	49,304	$0.18M	0.0%	-74.7%	0.035%
8/14/2024	Marshall Wace LLP	1,144,051	$4.12M	0.0%	N/A	0.816%
8/14/2024	Integral Health Asset Management LLC	1,775,000	$6.39M	0.6%	+86.8%	1.266%
8/13/2024	Rubric Capital Management LP	15,307,347	$55.11M	1.4%	+12.9%	10.914%
8/9/2024	Renaissance Technologies LLC	1,762,003	$6.34M	0.0%	+5.4%	1.256%
8/7/2024	Monaco Asset Management SAM	348,128	$1.25M	0.2%	-14.0%	0.248%
8/7/2024	PFG Investments LLC	17,000	$61K	0.0%	-45.5%	0.012%
8/1/2024	Rhumbline Advisers	6,958	$25K	0.0%	+70.9%	0.005%
5/16/2024	Janus Henderson Group PLC	5,120,573	$16.95M	0.0%	N/A	3.651%
5/16/2024	Knoll Capital Management LLC	260,470	$0.86M	0.5%	+62.3%	0.186%
5/15/2024	Price T Rowe Associates Inc. MD	991,971	$3.27M	0.0%	N/A	0.707%
5/13/2024	Index Fund Advisors Inc.	30,000	$99K	0.0%	N/A	0.021%
5/9/2024	Monaco Asset Management SAM	405,000	$1.34M	0.4%	-40.1%	0.324%
5/8/2024	Advisors Preferred LLC	8,262	$28K	0.0%	N/A	0.007%
5/7/2024	SG Americas Securities LLC	16,221	$54K	0.0%	N/A	0.013%
5/1/2024	BNP Paribas Financial Markets	17,435	$58K	0.0%	+581,066.7%	0.014%
2/15/2024	Forefront Analytics LLC	36,124	$83K	0.0%	-45.0%	0.029%
2/14/2024	Rubric Capital Management LP	13,552,997	$31.31M	0.6%	+16.7%	10.843%
2/13/2024	NEOS Investment Management LLC	351,905	$0.81M	0.1%	+751.5%	0.282%
2/9/2024	Primecap Management Co. CA	54,000	$0.13M	0.0%	-31.6%	0.043%
2/7/2024	Monaco Asset Management SAM	676,494	$1.56M	0.5%	+13.6%	0.541%
2/2/2024	Golden State Equity Partners	20,300	$47K	0.0%	+41.0%	0.016%
1/31/2024	abrdn plc	1,551,082	$3.58M	0.0%	N/A	1.241%
1/18/2024	Clear Harbor Asset Management LLC	59,754	$0.14M	0.0%	-6.3%	0.048%
11/15/2023	Tejara Capital Ltd	3,215,001	$4.15M	2.4%	+5.8%	2.572%
11/15/2023	Rock Springs Capital Management LP	7,676,481	$9.90M	0.3%	+9.0%	6.142%
11/15/2023	Adage Capital Partners GP L.L.C.	800,000	$1.03M	0.0%	N/A	0.640%
11/14/2023	683 Capital Management LLC	6,000,000	$7.74M	0.6%	+11.1%	4.800%
11/14/2023	Primecap Management Co. CA	79,000	$0.10M	0.0%	-49.9%	0.063%
11/13/2023	Tejara Capital Ltd	3,215,001	$4.15M	3.1%	+5.8%	2.572%
11/9/2023	Formidable Asset Management LLC	331,914	$0.43M	0.1%	N/A	0.266%
11/8/2023	Forefront Analytics LLC	65,649	$85K	0.0%	-20.7%	0.053%
11/7/2023	Monaco Asset Management SAM	595,729	$0.77M	0.2%	-15.6%	0.477%
11/6/2023	Privium Fund Management UK Ltd	24,726	$32K	0.0%	-86.0%	0.020%
10/26/2023	Clear Harbor Asset Management LLC	63,754	$82K	0.0%	+12.3%	0.051%
8/14/2023	683 Capital Management LLC	5,400,000	$7.13M	0.5%	+170.0%	4.320%
8/14/2023	Rock Springs Capital Management LP	7,042,391	$9.30M	0.2%	+12.8%	5.634%
8/14/2023	Mangrove Partners	5,531,547	$7.30M	0.5%	N/A	4.426%
8/11/2023	Rubric Capital Management LP	11,616,120	$15.33M	0.7%	+12.1%	9.294%
8/11/2023	Tejara Capital Ltd	3,037,971	$4.01M	2.0%	+24.7%	2.431%
8/8/2023	Monaco Asset Management SAM	705,729	$0.93M	0.3%	-46.4%	0.565%
8/3/2023	PFG Investments LLC	31,500	$42K	0.0%	-33.7%	0.025%
7/26/2023	Privium Fund Management B.V.	177,200	$0.23M	0.1%	N/A	0.142%
7/21/2023	Clear Harbor Asset Management LLC	56,754	$75K	0.0%	-29.7%	0.045%
5/12/2023	Tejara Capital Ltd	2,435,806	$1.72M	0.9%	+11.3%	1.949%
5/12/2023	Forefront Analytics LLC	83,700	$59K	0.0%	+13.9%	0.067%
5/11/2023	PFG Investments LLC	47,500	$34K	0.0%	N/A	0.038%
5/9/2023	Formidable Asset Management LLC	331,914	$0.23M	0.0%	+15.2%	0.266%
2/14/2023	683 Capital Management LLC	125,000	$94K	0.0%	N/A	0.100%
2/13/2023	Forefront Analytics LLC	73,500	$55K	0.0%	-34.8%	0.059%
2/3/2023	Monaco Asset Management SAM	2,049,661	$1.54M	0.4%	+998.1%	1.640%
1/31/2023	Monaco Asset Management SAM	2,049,661	$1.54M	0.5%	+998.1%	1.640%
1/20/2023	Clear Harbor Asset Management LLC	84,000	$63K	0.0%	-42.1%	0.067%
11/14/2022	Point72 Asset Management L.P.	9,829,354	$8.46M	0.0%	-2.1%	7.864%
11/14/2022	Clearline Capital LP	3,957,135	$3.41M	0.4%	+29.4%	3.166%
11/14/2022	Rubric Capital Management LP	10,366,120	$8.93M	0.4%	-38.1%	8.294%
11/14/2022	Forefront Analytics LLC	112,800	$96K	0.1%	+48.7%	0.090%
11/7/2022	Virtu Financial LLC	33,880	$29K	0.0%	N/A	0.027%
11/3/2022	Barclays PLC	39,470	$34K	0.0%	+97.4%	0.032%
11/1/2022	Privium Fund Management UK Ltd	177,200	$0.15M	0.2%	N/A	0.142%
10/31/2022	Monaco Asset Management SAM	186,656	$0.16M	0.1%	N/A	0.160%
10/25/2022	Clear Harbor Asset Management LLC	145,000	$0.13M	0.0%	-10.5%	0.124%
8/16/2022	Formidable Asset Management LLC	275,556	$0.31M	0.1%	N/A	0.236%
8/16/2022	DAFNA Capital Management LLC	1,096,513	$1.23M	0.3%	-9.9%	0.937%
8/15/2022	Clearline Capital LP	3,058,596	$3.43M	0.4%	+135.0%	2.615%
8/15/2022	Point72 Asset Management L.P.	10,035,970	$11.24M	0.0%	-12.7%	8.579%
8/12/2022	Ikarian Capital LLC	615,856	$0.20M	0.0%	-32.8%	0.526%
8/11/2022	Primecap Management Co. CA	321,660	$0.36M	0.0%	-2.8%	0.275%
8/10/2022	Forefront Analytics LLC	75,850	$83K	0.0%	N/A	0.065%
7/25/2022	Silverarc Capital Management LLC	156,195	$0.18M	0.1%	-33.7%	0.134%
7/20/2022	Clear Harbor Asset Management LLC	162,000	$0.19M	0.0%	+589.4%	0.138%
5/17/2022	Rock Springs Capital Management LP	6,074,943	$6.80M	0.2%	+8.8%	5.193%
5/16/2022	Clearline Capital LP	1,301,783	$1.46M	0.2%	+89.7%	1.113%
5/16/2022	J. Goldman & Co LP	217,051	$0.24M	0.0%	+221.6%	0.186%
5/16/2022	Eversept Partners LP	370,170	$0.42M	0.0%	+42.7%	0.316%
5/16/2022	Maven Securities LTD	544,458	$0.61M	0.0%	+72.6%	0.465%
2/15/2022	Rubric Capital Management LP	14,914,447	$23.86M	1.1%	+32.0%	22.001%
2/15/2022	Sender Co & Partners Inc.	333,904	$0.53M	0.3%	N/A	0.493%
2/15/2022	Shay Capital LLC	48,052	$77K	0.0%	N/A	0.071%
2/15/2022	Commodore Capital LP	1,954,970	$3.13M	0.7%	-0.9%	2.884%
2/14/2022	Clearline Capital LP	686,292	$1.10M	0.1%	N/A	1.012%
2/14/2022	Bluefin Capital Management LLC	37,300	$60K	0.0%	N/A	0.055%

Data available starting January 2016

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Today's Range

Now: $3.72

$3.65

$3.81

50 Day Range

MA: $4.15

$3.33

$4.62

52 Week Range

Now: $3.72

$3.17

$5.02

Volume

831,466 shs

Average Volume

1,326,627 shs

Market Capitalization

$2.89 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Mereo BioPharma Group?: Mereo BioPharma Group's top insider investors include:
Denise Scots-Knight (CEO)
Charles Sermon (General Counsel)
Christine Ann Fox (CFO)
John A Lewicki (Insider)
Alexandra Hughes-Wilson (Insider)
Deepika Pakianathan (Director)
Learn More about top insider investors at Mereo BioPharma Group.
Who are the major institutional investors of Mereo BioPharma Group?: Mereo BioPharma Group's top institutional investors include:
Janus Henderson Group PLC — 8.80%
Frazier Life Sciences Management L.P. — 3.63%
Clearline Capital LP — 2.31%
Acuta Capital Partners LLC — 0.90%
Jane Street Group LLC — 0.00%
HealthInvest Partners AB — 0.14%
Learn More about top institutional investors of Mereo BioPharma Group stock.
Which major investors are selling Mereo BioPharma Group stock?: In the previous quarter, MREO stock was sold by these institutional investors:
Verition Fund Management LLC
Clearline Capital LP
Jane Street Group LLC
Within the last year, company insiders that have sold Mereo BioPharma Group company stock include:
Denise Scots-Knight (CEO)
Charles Sermon (General Counsel)
Christine Ann Fox (CFO)
John A Lewicki (Insider)
Alexandra Hughes-Wilson (Insider)
Deepika Pakianathan (Director)
Learn More investors selling Mereo BioPharma Group stock.
Which major investors are buying Mereo BioPharma Group stock?: During the last quarter, MREO stock was bought by institutional investors including:
Janus Henderson Group PLC
Frazier Life Sciences Management L.P.
Acuta Capital Partners LLC
HealthInvest Partners AB
GSA Capital Partners LLP
Fred Alger Management LLC
Polar Asset Management Partners Inc.
State Street Corp